Rx License-Rx
← Back to AI Screener Open university listing

LicenseRx asset brief

A Genetic System in Yeast for Functional Identification of Human p53 Mutations

National Institutes of Health Preclinical Cell/Gene Therapy
Probability of Success

23% · grade C · Medium data confidence

Model PoS 23% (grade C, medium data confidence). Strongest signals: Data maturity, Indication pull. Biggest drag: IP position.

Data maturity (22%) 64

Preclinical; in vivo data, human data.

IP position (16%) 30

Protection lapsed or abandoned -- verify freedom to operate.

Modality feasibility (14%) 55

Cell/gene therapy -- high upside, heavy manufacturing and regulatory load.

Indication pull (14%) 82

Oncology -- active buyer appetite.

Competitive whitespace (12%) 78

Under-served segment; crowded oncology field; multi-modal differentiation.

Translational evidence (12%) 62

Public evidence mentions: human, in vivo.

Licensing readiness (10%) 94

Listed as available for licensing; established tech-transfer office; 1 public source link(s).

Unlock the full strategic deep dive

Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.

View Operator access See what's included →